Diffusion Pharmaceuticals (NASDAQ:DFFN) Upgraded to Buy by HC Wainwright
Diffusion Pharmaceuticals (NASDAQ:DFFN) Upgraded to Buy by HC Wainwright
HC Wainwright upgraded shares of Diffusion Pharmaceuticals (NASDAQ:DFFN – Get Rating) from a neutral rating to a buy rating in a research note published on Tuesday morning, The Fly reports. HC Wainwright currently has $9.50 price objective on the stock.
Separately, StockNews.com upgraded shares of Diffusion Pharmaceuticals from a sell rating to a hold rating in a report on Monday.
Get Diffusion Pharmaceuticals alerts:Diffusion Pharmaceuticals Price Performance
NASDAQ DFFN opened at $6.90 on Tuesday. Diffusion Pharmaceuticals has a 12 month low of $5.10 and a 12 month high of $31.50. The firm has a market capitalization of $14.07 million, a PE ratio of -0.56 and a beta of 1.59. The company's 50 day simple moving average is $7.34 and its 200 day simple moving average is $12.46.
Institutional Trading of Diffusion Pharmaceuticals
Large investors have recently added to or reduced their stakes in the business. Trexquant Investment LP bought a new stake in Diffusion Pharmaceuticals during the second quarter worth approximately $71,000. JPMorgan Chase & Co. acquired a new position in Diffusion Pharmaceuticals in the 1st quarter worth approximately $106,000. Finally, Renaissance Technologies LLC boosted its stake in Diffusion Pharmaceuticals by 8.3% in the 1st quarter. Renaissance Technologies LLC now owns 1,324,202 shares of the company's stock worth $331,000 after purchasing an additional 101,100 shares during the period.About Diffusion Pharmaceuticals
(Get Rating)
Diffusion Pharmaceuticals Inc, a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc was founded in 2001 and is based in Charlottesville, Virginia.
Read More
- Get a free copy of the StockNews.com research report on Diffusion Pharmaceuticals (DFFN)
- Are These 3 Video Game Stocks Now In Play?
- 2 Long-Term EV Plays Trading Under $20
- Exxon, Occidental Petroleum Lead Heavy Month Of Insider Buying
- Why Apple is Primed to Take a Bite Out of Live Sports
- Home Depot Results Point To Sluggish 2nd Half
Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
HC Wainwright升級了以下股票擴散製藥(納斯達克:DFFN-GET評級)據The Fly報道,在週二上午發佈的一份研究報告中,評級從中性轉為買入。HC Wainwright目前對該股的目標價為9.50美元。
另外,StockNews.com在週一的一份報告中將擴散製藥的股票評級從賣出評級上調為持有評級。
到達擴散製藥公司警報:擴散藥品價格表現
納斯達克DFFN週二開盤報6.9美元。Diffect PharmPharmticals的12個月低點為5.10美元,12個月高點為31.50美元。該公司市值為1,407萬美元,本益比為-0.56,貝塔係數為1.59。該公司的50日簡單移動均線切入位在7.34美元,200日簡單移動均線切入位在12.46美元。
擴散藥品的制度性交易
大型投資者最近增持或減持了該公司的股份。Trexquant Investment LP在第二季度購買了擴散製藥公司的新股份,價值約71,000美元。今年第一季度,摩根大通收購了擴散製藥公司的一個新頭寸,價值約10.6萬美元。最後,復興科技有限責任公司在第一季度將其在擴散製藥公司的股份增加了8.3%。復興科技有限責任公司在此期間又購買了101,100股,現在擁有1,324,202股該公司股票,價值331,000美元。關於擴散製藥
(獲取評級)
擴散製藥公司是一家生物製藥公司,該公司開發新的療法,以增強人體輸送氧氣的能力。它的主要候選產品是反式番茄酸鈉,開發這種藥物是為了促進氧氣向組織的擴散,以及治療新冠肺炎病。擴散製藥公司成立於2001年,總部設在弗吉尼亞州夏洛茨維爾。
閱讀更多內容
- 免費獲取StockNews.com關於擴散藥物的研究報告(DFFN)
- 這3只電子遊戲股票現在還在玩嗎?
- 2輛長期電動汽車的交易價格低於20美元
- 埃克森美孚和西方石油導致內幕人士本月大量買入
- 蘋果為何準備退出體育直播
- 家得寶業績指向低迷的下半年
獲得《擴散醫藥日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收最新新聞和分析師對擴散製藥及相關公司評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧